RBC Capital lowered the firm’s price target on Clorox (CLX) to $127 from $132 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q1 results in Home and Personal Care, Beverages, and Packaged Food categories, The March quarter should be fine, characterized by a still sluggish top-line environment, though much of the emphasis will be on forward commentary due to Middle East conflict, which has created top-line and inflationary risks, the analyst tells investors in a research note. This ceasefire announcement is a positive but the firm still expects lingering impacts and elevated commodity prices relative to prior to the conflict, RBC added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLX:
- Clorox price target lowered to $110 from $125 at Wells Fargo
- Clorox price target lowered to $110 from $121 at UBS
- Balanced Risk-Reward on Clorox: Limited Near-Term Upside Despite GOJO-Driven Revenue Boost and ERP-Inflated Growth Comparisons
- Clorox Completes Acquisition of Purell Maker GOJO Industries
- Clorox completes acquisition of Gojo Industries
